117 F. Supp. 3d 549
D. Del.2015Background
- Bayer/Intendis/Intraserv own U.S. Patent No. 6,534,070 (the '070 patent) claiming azelaic acid hydrogels (Finacea®) for topical treatment of rosacea; Glenmark filed an ANDA seeking approval for a generic 15% azelaic acid gel with a Paragraph IV certification.
- Finacea® development: Schering/Bayer reformulated a 20% azelaic acid cream (Skinoren®) into a 15% hydrogel (Finacea®) to solve cream instability, improve cosmetics, and preserve efficacy; example and Franz diffusion cell data in the patent showed higher skin retention/penetration for the hydrogel.
- Glenmark’s accused product substituted isopropyl myristate for the patent’s lecithin/triglycerides but otherwise matched many excipients and manufacturing steps; Glenmark’s Franz and clinical tests concluded bioequivalence to Finacea®.
- The court held a bench trial on infringement and validity (Markman hearing and five-day trial); key disputed issues: construction of “hydrogel” and whether Glenmark’s substituted excipient is equivalent to claimed lecithin/triglycerides (doctrine of equivalents), plus obviousness.
- The court found claim construction (hydrogel may include dispersed particles/insoluble liquids), concluded infringement under the doctrine of equivalents (isopropyl myristate acts as a penetration enhancer substantially the same function/way/result), and held the asserted claims valid (not obvious).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Construction of “hydrogel” | Patent contemplates a gel that (in preferred embodiments) lacks nanoemulsion vesicles, but a gel can be formed from aqueous polymer; limit should not read out dispersed/insoluble liquids | Hydrogel should exclude insoluble liquid/emulsion phases so Glenmark’s product (if containing such) would not literally infringe | Court: “hydrogel” = semisolid dosage form containing water and gelling agent, which may contain dispersed particles and/or insoluble liquids (so not limited to vesicle‑free embodiments) |
| Infringement under doctrine of equivalents (isopropyl myristate v. lecithin/triglycerides) — Function | Lecithin/triglycerides perform as penetration enhancers causing greater azelaic acid delivery; Glenmark’s isopropyl myristate performs same function | Defendants dispute lecithin/triglycerides were the cause (dissolved fraction/different factors); challenge experimental reliability | Court: evidence (including parties’ ANDA statements, experts, and comparative Franz/clinical data) supports that all three can act as penetration enhancers; function prong met |
| Infringement — Way & Result | Plaintiffs: all three excipients disrupt stratum corneum lipids producing increased delivery; result is therapeutically effective delivery into living skin | Defendants: different mechanistic sub‑routes (dissolution vs. fluidization) and flux curve differences defeat equivalence; also rely on their bioequivalence testing | Court: mechanistic distinctions insufficient — claimed patent did not require a specific sub‑mechanism; way and result satisfied; doctrine of equivalents infringement found for all asserted claims |
| Invalidity — Obviousness & Estoppel/Ensnarement defenses | Plaintiffs: prior art does not teach an azelaic acid hydrogel with claimed combination; unexpected Franz/scarification results and commercial success support nonobviousness; prosecution history does not estop equivalents | Defendants: prior art (emulsions, microemulsions, and azelaic acid formulations) would motivate a POSITA to make an azelaic hydrogel and substitute penetration enhancers; argue ensnarement and prosecution history estoppel | Court: defendants failed to prove obviousness by clear and convincing evidence; only Maru disclosed an azelaic hydrogel and the record lacked proof of motivation/expectation of success to combine references; no estoppel or ensnarement barred equivalents |
Key Cases Cited
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (claim construction principles; read claims in view of specification)
- Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576 (Fed. Cir. 1996) (intrinsic evidence is primary source for claim meaning)
- Markman v. Westview Instruments, Inc., 52 F.3d 967 (Fed. Cir. 1995) (claim construction framework)
- Exergen Corp. v. Wal‑Mart Stores, Inc., 575 F.3d 1312 (Fed. Cir. 2009) (direct infringement requires each claim limitation)
- Warner‑Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17 (1997) (doctrine of equivalents and function‑way‑result test)
- Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605 (1950) (classic statement of the doctrine of equivalents)
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002) (prosecution history estoppel limits equivalents)
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 344 F.3d 1359 (Fed. Cir. 2003) (en banc) (presumption and exceptions for estoppel)
- Abbott Labs. v. TorPharm, Inc., 300 F.3d 1367 (Fed. Cir. 2002) (ANDA specifications can control infringement inquiry)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (obviousness framework; reason to combine and common sense)
- Octane Fitness, LLC v. ICON Health & Fitness, Inc., 572 U.S. 545 (2014) (standard for awarding attorneys’ fees under 35 U.S.C. § 285)